Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 13/20 | 0.48 |
| ▸ | CES1 | P23141 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5145030 | 0.84 | AKR1C3 (0.50) | ALDH1A1TDP1ABCB11NR3C1CYP1A2 | |
| SCHEMBL3415350 | 0.84 | CES2 (0.50) | CES2CES1ALDH1A1TDP1CYP3A4 | |
| SCHEMBL1110888 | 0.82 | ALDH1A1 (0.50) | ALDH1A1TDP1ABCB11NR3C1CYP1A2 | |
| SCHEMBL6836218 | 0.80 | CES2 (0.58) | CES2CES1ALDH1A1ALOX15RAB9A | |
| SCHEMBL14033994 | 0.77 | ALDH1A1 (0.45) | ALDH1A1TDP1ABCB11NR3C1CYP1A2 | |
| SCHEMBL6573452 | 0.77 | ALDH1A1 (0.44) | CES2CES1ALDH1A1TDP1ABCB11 | |
| SCHEMBL29498981 | 0.76 | AKR1C3 (0.44) | ALDH1A1TDP1ABCB11NR3C1CYP1A2 | |
| SCHEMBL28285905 | 0.76 | AKR1C3 (0.44) | ALDH1A1TDP1ABCB11NR3C1CYP1A2 | |
| SCHEMBL8574337 | 0.74 | CES2 (0.78) | CES2CES1ALDH1A1ALOX15RAB9A | |
| SCHEMBL28373751 | 0.73 | MAPT (0.54) | ALDH1A1TDP1CYP1A2CYP3A4ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210289832-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3849347-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210213091-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | Poviva Corp. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. | 2021-05-20 | — | — | US | disclosed |
| EP-3810135-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Poviva Corp. (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3780976-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | Poviva Corp. (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20210045998-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | Poviva Corp. | 2021-02-18 | — | — | US | disclosed |
| EP-3765088-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | Poviva Corp. (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200178572-A1 | MICROWAVE PROCESSING METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS | Poviva Corp. | 2020-06-11 | — | — | US | disclosed |
| WO-2020056344-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | POVIVA TEA, LLC (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019204502-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | POVIVA TEA, LLC (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019178360-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | POVIVA TEA, LLC (US) | 2019-09-19 | — | — | WO | disclosed |
| US-7658956-B2 | Erectile dysfunction phyto-nutraceutical synergistic composition | Olalde Rangel, Jose Angel | 2010-02-09 | — | — | US | disclosed |
| US-20080026082-A1 | ERECTYLE DISFUNCTION PHYTO-NUTRACEUTICAL SYNERGISTIC COMPOSITION | OLALDE RANGEL JOSE ANGEL | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200178572-A1 | MICROWAVE PROCESSING METHODS FOR FORMULATING ORALLY INGESTIBLE COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE AGENTS | PNLIP, LIPC, LIPA | CES2 2731/4885CES1 1271/4885ALDH1A1 2657/4885 |
| US-20210045998-A1 | TRANSDERMAL AND/OR DERMAL DELIVERY OF LIPOPHILIC ACTIVE AGENTS | LIPA, MMP8, MMP1 | CES2 147/4885CES1 770/4885ALDH1A1 2693/4885 |
| US-20210145036-A1 | LIPOPHILIC ACTIVE AGENT INFUSED COMPOSITIONS WITH REDUCED FOOD EFFECT | LIPC, PNLIP, LIPA | CES2 104/4885CES1 141/4885ALDH1A1 2004/4885 |
| US-20210145841-A1 | ENHANCEMENT OF DELIVERY OF LIPOPHILIC ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | FABP7, LIPA, LIPC | CES2 14/4885CES1 60/4885ALDH1A1 2589/4885 |
| US-20210213091-A1 | LIPOPHILIC ACTIVE AGENT INFUSED TOBACCO LEAVES AND/OR TOBACCO MATERIALS AND METHODS OF USE THEREOF | MGLL, LIPA, LAMP1 | CES2 72/4885CES1 916/4885ALDH1A1 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.